↓ Skip to main content

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

Overview of attention for article published in Frontiers in oncology, December 2020
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Published in
Frontiers in oncology, December 2020
DOI 10.3389/fonc.2020.602185
Pubmed ID
Authors

Longfeng Zhang, Yongfu Hang, Maobai Liu, Na Li, Hongfu Cai

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Lecturer 3 13%
Student > Bachelor 3 13%
Student > Master 2 8%
Student > Postgraduate 2 8%
Student > Ph. D. Student 2 8%
Other 4 17%
Unknown 8 33%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 4 17%
Medicine and Dentistry 4 17%
Business, Management and Accounting 2 8%
Immunology and Microbiology 2 8%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 3 13%
Unknown 8 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 January 2021.
All research outputs
#17,297,846
of 25,387,668 outputs
Outputs from Frontiers in oncology
#8,033
of 22,433 outputs
Outputs of similar age
#323,271
of 518,269 outputs
Outputs of similar age from Frontiers in oncology
#229
of 669 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,433 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 518,269 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 669 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.